Oxygen and Cancer: friend or foe?. Part 1: Scientific part Dirk de Ruysscher Part 2: Organisational part Harald Moonen.

Slides:



Advertisements
Similar presentations
2 E Conférence Québécoise Sur La Résistance Thérapeutique du Cancer Q-CROC Montréal, November 5-6, 2010.
Advertisements

Use of PET to Biologically Characterize Tumors and Monitor Their Response to Treatment Juan A del Regato Lecture Stanford 2004 Lester J Peters MD Peter.
Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.
History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.
Role of Nodal Irradiation in Breast Cancer
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Some remaining questions in particle therapy radiation biology Bleddyn Jones University of Oxford 1. Gray Institute for Radiation Oncology & Biology 2.
Radiation Therapy (RT). What is cancer? Failure of the mechanisms that control growth and proliferation of the cells Uncontrolled (often rapid) growth.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.
Radiotherapy for Kidney cancer
Time, Dose, and Fractionation
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
Molecular Biomarkers in Radiotherapy of Cervical Cancer A collaboration project between Department of Gynecologic Oncology and Department of Radiation.
Dr. Rico Liu Consultant, Department of Clinical Oncology, Queen Mary Hospital Honorary Clinical Associate Professor, Department of Clinical Oncology, The.
Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:
IMRT for the Treatment of Anal Cancer Kristen O’Donnell, MS3 December 12, 2007.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 100 Basic Principles of Cancer Chemotherapy.
1 Non–Small-Cell Lung Cancer Diagnosis and Staging EvaluationPurpose Physical examinationIdentify signs Chest x-rayDetermine position, size, number of.
Birga Terlunen-Traboldt ENT-Journal Club Need for Neck dissection after Radiochemotherapy? A study of the French GETTEC Group Vedrine P;Thariat J;Hitier.
CLINICAL TRIALS WITH BIOLOGICAL ENDPOINT IN ESOGASTRIC CANCER
Tumors Models, and Response of Tumors Martin Brown April 23, 2012
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Incidence of Childhood Cancer. What is cancer ? Uncontrolled growth of cells Are these cancer cells abnormal? No, but their behaviour is.
Are there benefits from chemotherapy to early endometrial cancer
TREATMENT PLANNING Modelling chemo-hadron therapy Lara Barazzuol | Valencia | 19 June 2009.
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.
Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.
RTOG1106: Randomized Phase IIR Trial of Personalized Adaptive Radiotherapy Based on Mid-treatment FDG-PET in Locally Advanced NSCLC P.I.: Feng-Ming (Spring)
ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/2/09.
Definitive radiotherapy for head and neck cancer: the use of physical exam versus computed tomography to manage the post-RT neck Stanley Liauw*, Robert.
Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica
Power of science implemented in life quality Improvement of the effectiveness of radiation therapy with radiomodification by Polyplatillen and Fluoropyrimidine.
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
Validity of more than 30Gy radiation therapy for long-surviving patients with painful bone metastases E.Katayama 1,2, H.Okada 1, I.Asakawa 2, T.Tamamoto.
ACRIN 6682 Phase II Trial of 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 9/30/10.
Adjuvant radiochemotherapy in head and neck tumors H. Christiansen and C. F. Hess Department of Radiotherapy Goettingen University.
Hypoxia in Soft-Tissue Sarcomas on [ 18 F]- Fluoroazomycin Arabinoside Positron Emission Tomography (FAZA-PET) Powerfully Predicts Response to Radiotherapy.
Cancer Notes. What is cancer? Cancer develops when cells in the body begin to grow out of control.
The 4 Rs Repair Redistribution Repopulation Reoxygenation.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Mathematical Modelling within Radiotherapy: The 5 R’s of Radiotherapy and the LQ model. Helen McAneney 1 and SFC O’Rourke 1,2 1 School Mathematics and.
GBM – Oncological Management Dr H Lord Consultant Clinical Oncologist.
Cancer Basics EQ: What does cancer have to do with the cell cycle?
Background Carcinoma of the anal canal accounts for 1.5% of all digestive system malignancies in the United States. 1 The annual incidence continues to.
Journal Club Dept. Of Medical Physics Faculty of Medicine Iran Uni. Of Medical Sciences Hyperthermia SR Mahdavi 1395/07/27.
ACRIN 6682 Phase II Trial OF 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/4/08.
Albert J. Chang, MD, PhD 1 Farrokh Dehdashti, MD 2 Perry W. Grigsby, MD, MS 1 Department of Radiation Oncology 1 Department of Radiology and Nuclear Medicine.
Cancer Objective What is Cancer? Cancer is uncontrolled cell growth. (Mitosis) When you are young, your cells grow fast so because you are growing.
Karolina Kokurewicz Supervisors: Dino Jaroszynski, Giuseppe Schettino
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
The use of Radiotherapy in Cancer.. What is radiotherapy? The treatment of cancer with ionising radiation is called Radiotherapy or Radiation Oncology.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Department of Clinical Radiotherapy, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK R4 한재준 1.
Chapter 12 Therapeutic Heating Applications of Radio Frequency Energy C-K. Chou.
Cell Division Gone Wrong Cancer.  Cancer is a disease of uncontrolled cell division. It starts with a single cell that loses its control mechanisms due.
RBE: open issues and next challenges Francesco Tommasino Workshop: la radiobiologia in INFN Trento, Maggio 2016.
Emily Tanzler, MD Waseet Vance, MD
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Radiotherapy for Metastatic Spinal Cord Compression
RADIOBIOLOGY Agnieszka Żyromska.
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.
Presentation transcript:

Oxygen and Cancer: friend or foe?

Part 1: Scientific part Dirk de Ruysscher Part 2: Organisational part Harald Moonen

Cancer = Genetic disease with 6 features

The 6 Hallmarks of Cancer

HYPOXIA = LACK OF OXYGEN

Tumor hypoxia Hypoxia

1 mm size

Normal colon Abnormal vasculature is a prime cause of hypoxia in cancer Corrosion castings Colon xenograft Tumor hypoxia

Two types of hypoxia

oxygen glucose conc Distance from vessel blood vessel

Heterogeneity in Oxygenation a)Amount (%) amongst patients b)In severity c)In space d)In time

Hypoxia tolerance/angiogenesis

Hypoxia tolerance varies amongst tumors

oxygen glucose conc Distance from vessel blood vessel

Tumour hypoxia, does it exist in human tumours?

Nordsmark et al. Acta Oncol 1994 pO 2 measurements indicate most tumors are hypoxic Oxygen partial pressure (mmHg) Normal tissue Relative frequency (%)

Median Oxygen Levels of Human Tumors Tumor TypeMedian pO 2 (mmHg) Reference Glioblastoma 5.6 (14 pts)Collingridge et al, 1999 Head & Neck 7.4 (41 pts) 4.6 (63 pts) Rudat et al, 2000 Brizel et al, 1999 Lung12.8 (26 pts)Le & Stevens (pers. comm.) Breast10.0 (15 pts)Vaupel et al, 2002 Pancreas 2.7 (7 pts)Koong et al, 2000 Cervix10.0 (51 pts) 5.0 (74 pts) Knocke et al, 1999 Fyles et al, 1998 Prostate 2.4 (59 pts) 4.5 (55 pts) Movsas et al, 2001 Parker et al, 2004 Soft Tissue Sarcoma 6.2 (34 pts)Brizel et al, 1996 Cf. normal = mmHg

Rischin, D. et al. J Clin Oncol; 24: (A) Baseline [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) of patient with T2N2b squamous cell carcinoma of the pyriform fossa with left nodal mass (A)Baseline [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) of patient with T2N2b squamous cell carcinoma of the pyriform fossa with left nodal mass. (B)(B) [18F]-fluoromisonidazole (FMISO) -PET at baseline, nonhypoxic primary tumor, and hypoxic node. (C)C) FDG-PET 12 weeks after chemoboost, complete response in nonhypoxic primary tumor, and poor response in hypoxic node. Residual tumor in nodal mass was confirmed pathologically after neck dissection.

Copyright ©2006 American Association for Cancer Research Rajendran, J. G. et al. Clin Cancer Res 2006;12: Prognostic value of F-MISO PET

Tumour hypoxia, does it matter?

The clinical importance of tumor hypoxia 1.Resistance to radiotherapy 2.Resistance to chemotherapy 3.Contribution to ‘malignancy’

Cure = min kill of 10 9 cells

90% cell death: Partial Remission, no cure 99,9% cell death: Complete remission, no cure 99, % cell death: Complete remission, Local control, Cure if no metastasis

Cell death N°1 = Mitotic death Stem cells? Dividing cells Unfit cells

1909 Gottwald Schwarz Vienna First clinical demonstration of hypoxia-mediated radioresistance

G. Steel, Basic Clinical Radiobiology 1997, second edition In vitro effect of hypoxic conditions on radiation-induced cellular lethality Cells are much more sensitive to x-rays in the presence of molecular oxygen than in its absence. The ratio of doses under hypoxia to those under oxia necessary to produce the same level of cell killing is close to 3. OER = 2.8 Hypoxic oxic Surviving fraction Radiation dose (Gy) OER (Oxygen enhancement ratio) = Radiation dose in hypoxia/ Radiation dose in air

Impact of hypoxia on survival in patients with cervical cancer and definitive radiotherapy pO 2 < 10mmHg, n = 23 pO 2 > 10mmHg, n = 19 Radiotherapy Time (months) Overall survival probability Log-rank p = Höckel M. et al. Cancer Res 56, (1996)

cytotoxic drug drug conc Distance from vessel blood vessel resistance to radiation

Impact of pretreatment on prognosis in surgically treated patients with cervical cancer Höckel M. et al, 1996 Overall survival Surgery pO 2 > 10 mm Hg, n = 22 pO 2 < 10 mm Hg, n=25 Log-rank n = Time (months)

Treatment of hypoxic cells: One example: To kill hypoxic cells with a “bioreductive drug” Non toxic prodrugToxic drug Hypoxia

Mechanism Tirapazamin Selectivity for tumors: in hypoxia: TPZ radical is formed which causes DNA breaks in aerobic conditions: TPZ radical is reoxidized towards the parent compound with the production of superoxide radicals which are moderately cytotoxic

Exploit hypoxia: tirapazamine, a bioreductive drug Tirapazamine - a hypoxia selective cytotoxin

Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Rischin D et al. JCO 05 Jan 1;23(1):79-87.

Rischin D et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). JCO 05 Jan 1;23(1): Effect on normal tissues

Rischin, D. et al. J Clin Oncol; 24: Time to local failure (Kaplan-Meier method) by treatment arm and hypoxia in the primary tumor (censored times are indicated as tick marks on the curves)

2 Gy extra 2 Gy during the same fraction

Does hemoglobin has a prognostic value in human cancer ?

Hb is associated with locoregional control of head and neck cancer by RT Lee et al. (RTOG 85-27), IJROBP 42:1069, Years from randomization MalesFemales Low Hb< 14.5< 13.0 g/dl High Hb  14.5  13.0 g/dl 48.3% Low Hb 51.6% 65.9% 67.8% High Hb p = Locoregional Failure (%)

Overgaard (1988) Squamous Ca larynx/pharynx 1112 patients

Tumour Hypoxia: - related to treatment resistance - related to tumour aggressiveness BUT ALSO - a unique therapeutic opportunity! Oxidative damage: Plays a role in carcinogenesis